Last reviewed · How we verify

Purdue Pharma, Canada — Portfolio Competitive Intelligence Brief

Purdue Pharma, Canada pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PRC-063 oral capsules PRC-063 oral capsules phase 3 Serotonin-norepinephrine reuptake inhibitor (SNRI) Pain, Depression

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Eli Lilly and Company · 1 shared drug class
  3. Jefferson Clinic, P.C. · 1 shared drug class
  4. Ministry of Health & Welfare, Korea · 1 shared drug class
  5. National Institute of Mental Health (NIMH) · 1 shared drug class
  6. New York State Psychiatric Institute · 1 shared drug class
  7. North Dakota State University · 1 shared drug class
  8. Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Purdue Pharma, Canada:

Cite this brief

Drug Landscape (2026). Purdue Pharma, Canada — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/purdue-pharma-canada. Accessed 2026-05-14.

Related